3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myeloid, Acute
19
Precursor Cell Lymphoblastic Leukemia-Lymphoma
17
Primary Myelofibrosis
12
Polycythemia Vera
11
Myelodysplastic Syndromes
10
Leukemia
10
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
9
Myeloproliferative Disorders
8
Recurrence
6
Leukemia, Myelomonocytic, Chronic
6
Hematologic Neoplasms
6
Breast Neoplasms
6
Myelodysplastic-Myeloproliferative Diseases
5
Lymphoma, T-Cell
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Hodgkin Disease
5
Graft vs Host Disease
5
Thrombocythemia, Essential
4
Leukemia, Myeloid, Chronic-Phase
4
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Multiple Myeloma
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Leukemia, Prolymphocytic, T-Cell
3
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
3
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Interventions
Fulvestrant
2
ruxolitinib
1
dexpanthenol
1
ceterizine hydrochloride
1
capivasertib
1
benralizumab
1
Triamcinolone Acetonide
1
Tetracycline
1
Provitamins
1
Prednisone
1
Minocycline
1
Loperamide
1
Interviews as Topic
1
Hydrocortisone
1
HIV Testing
1
Gels
1
Fibroblast Growth Factor 7
1
Erlotinib Hydrochloride
1
Doxycycline
1
Dapsone
1
Clindamycin
1
Cetuximab
1
Anti-Bacterial Agents
1
Alpelisib
1
Acitretin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Exanthema
×
ruxolitinib
×
Clear all
NCT06399029
2026-04-30
TRUX-LST
University of Zurich
Phase 2
Active not recruiting
22 enrolled